Text and Data Mining valid from 2019-04-25
Received: 20 April 2018
Revised: 18 March 2019
Accepted: 20 March 2019
First Online: 25 April 2019
Compliance with ethical standards
: Kris Elverum is the Senior Vice President of Corporate Development for Turnstone Biologics, a privately held immuno-oncology company developing novel viral immunotherapies for cancer. Previously, Mr. Elverum worked at Novartis, the company that launched tisagenlecleucel. Maria Whitman is a Principal at ZS Associates, a global professional services company whose clients include most pharmaceutical and biotech companies, including some with recent cell and gene therapy approvals named in the review article and others with drugs in pipeline. Some of the experts interviewed for this review article were attained through an expert panel vendor, and may have received an honoraria for their interview, in which case ZS Associates paid for these interviews, however all experts independently agreed to be named as contributors for this review.